Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeted Plasma Proteomics Reveals a Central Role of Upregulated TNFRSF Proteins in HIV-associated Stroke: A Cross-sectional Discovery and Longitudinal Validation Study

ABSTRACT: This study investigated circulating proteomic signatures associated with stroke in people with HIV (PWH) using a nested case–control design. Plasma samples were collected from 135 HIV-positive individuals with stroke (HIV+/Stroke+), 135 HIV-positive stroke-free controls (HIV+/Stroke−), and 135 HIV-negative stroke-free controls (HIV−/Stroke−) from the CHART cohort (Taizhou, China). A longitudinal sub-cohort of 37 HIV+/Stroke+ individuals with paired pre- and post-stroke samples was additionally included for temporal validation. All plasma samples were profiled using the Olink Target 96 Cardiovascular II and Cardiovascular III panels simultaneously, quantifying 184 non-overlapping protein biomarkers. The study aimed to identify stroke-associated proteomic signatures, characterise underlying biological pathways and protein interaction networks, and validate key proteins longitudinally.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

DISEASE(S): Hemorrhagic Stroke,Stroke,Ischemic Stroke,Human Immunodeficiency Virus Infectious Disease

SUBMITTER: Tailin Chen

LAB HEAD: Na He

PROVIDER: PAD000032 | Pride | 2026-06-06

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	Longitudinal_validation_NPX_long.npx.csv	Csv
	Main_analysis_NPX_long.npx.csv	Csv
	checksum.txt	Txt

Items per page:

1 - 3 of 3

Similar Datasets

Cooking methods affect Advanced Glycation End products and lipid profiles: a randomized cross-over study in healthy subjects

Project description:Thermal treatments used in Ultra-Processed Foods (UPFs) lead to advanced glycation end products (AGEs) in food products. UPFs and serum AGEs are both associated with cardiometabolic disease. We explored differential cooking methods as a mechanistic link between UPFs and detrimental health outcomes. We performed a randomized cross-over cooking method trial in healthy subjects provided with identical ingredients.

2025-01-24 | PXD059624 | Pride

Longitudinal Olink affinity proteomics profiling of cytokine release syndrome in myeloma patients receiving BCMA-directed CAR-T therapy

Project description:This submission contains de-identified Olink NPX affinity proteomics data from longitudinal peripheral blood samples collected from patients with relapsed/refractory multiple myeloma treated with BCMA-directed CAR-T therapy (ide-cel or cilta-cel) in a prospective single-center pilot study. Samples were analyzed using the Olink Target 92 Immuno-Oncology panel to characterize inflammatory protein dynamics associated with cytokine release syndrome (CRS). In the associated study, these proteomic data were integrated with wearable physiologic monitoring to evaluate early CRS detection and to identify candidate biomarkers, including IFN-γ.

2026-04-28 | PAD000041 | Pride

Targeted plasma proteomics reveals organ damage signatures of AIDS-related and non-communicable chronic diseases-related deaths in HIV population

Project description:This project investigates the role of protein biomarkers in differentiating the underlying causes of mortality among people with HIV (PWH). With antiretroviral therapy (ART) significantly reducing deaths from opportunistic infections, noncommunicable chronic diseases (NCDs) have emerged as a leading cause of death in this population. Our study seeks to identify protein signatures that distinguish AIDS-related deaths from those due to NCDs, aiming to enhance early risk prediction and inform targeted interventions.

2025-04-15 | PAD000008 | Pride

People with HIV have higher percentages of circulating CCR5+ CD8+ T cells and lower percentages of CCR5+ regulatory T cells

Project description:CCR5 is the main HIV co-receptor. We aimed to (1) compare CCR5 expression on immune cells between people living with HIV (PLHIV) using combination antiretroviral therapy (cART) and HIV-uninfected controls, (2) relate CCR5 expression to viral reservoir size and (3) assess detereminants of CCR5 expression. Percentages of CCR5 positive cells (%) and CCR5 mean fluorescence intensity (MFI) assessed by flow cytometry in monocytes and lymphocyte subsets were correlated to host factors, HIV-1 cell-associated (CA)-RNA and CA-DNA, plasma inflammation markers and metabolites.

2022-08-12 | PXD031628 | Pride

Proteomic Profiling of MIS-C Patients Reveals Heterogeneity R 1 elating to Interferon 2 Gamma Dysregulation and Vascular Endothelial Dysfunction

Project description:The pathologic mechanisms causing Multisystem 38 Inflammatory Syndrome in Children (MIS-C) are not yet known; we sought to use high throughput proteomics to uncover signatures of dysregulation suggestive of pathophysiology fo this condition. MIS-C is a major complication of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic in pediatric patients. Weeks after an often mild or asymptomatic initial infection with SARS-CoV-2 children may present with a severe shock-like picture and marked inflammation. Children with MIS-C present with varying degrees of cardiovascular and hyperinflammatory symptoms. We performed a comprehensive analysis of more than 1400 proteins in the plasma proteome of children with SARS-CoV-2 and MIS-C.

2021-11-25 | PXD029375 | Pride

Human Plasma Discovery Proteomics

Project description:This study addresses this gap by conducting a direct comparison of eight platforms, representing both affinity-based and diverse mass spectrometry approaches, and covering over 13,000 proteins. By applying these platforms to the same cohort, we systematically assess their performance, identifying key differences and complementary strengths. Our findings offer valuable insights for researchers, highlighting trade-offs in coverage and their implications for biomarker discovery and clinical applications. This study serves as an essential resource, offering both technical evaluation and biological insights to support the development of novel diagnostics and therapeutics through plasma proteomics.

2025-10-10 | PAD000019 | Pride

Human Plasma Discovery Proteomics

2025-11-06 | PAD000022 | Pride

Pathogenic atypical Treg in ICI‑induced inflammatory arthritis and abrogation by IL‑6R blockadeblockade

Project description:OLINK proteomics of human synovial lines (MH7A) co-cultured with blood-derived Treg cells ofICI-IA patients, as compared to human synovial lines (MH7A) without co-culture system

2026-04-23 | PAD000037 | Pride

Evaluation of Olink Reveal Proximity Extension Assay for High-Throughput Proteomics: A Case Study Using NIST SRM 1950 and Spike-In Protein Standards

Project description:Plasma proteomics has regained attention in recent years through advancements in mass spectrometry instrumentation and sample preparation, as well as new high-throughput affinity-based technologies. Here, we evaluate the analytical performance of the new Olink Reveal platform, a proximity extension assay based technology quantifying 1,034 proteins across biological pathways. Using spiked-in recombinant Interleukin-10 (IL-10) and vascular endothelial growth factor D (VEGF-D) in the NIST SRM 1950 plasma standard, we assessed the linearity, sensitivity, precision and accuracy of the Olink assay. The results demonstrated strong linear relationships (R² 0.922–0.953) for both IL-10 and VEGF-D across spiked-in concentrations, confirming the robust technical performance of Olink Reveal and underscoring its suitability for relative quantitation in large-scale studies. The resulting data contains no sensitive or personally identifiable information, and is available in public repositories, and therefore suitable for use in benchmarking and software development.

2025-06-03 | PAD000009 | Pride

TIMEPOINT, a phase 1 study of MTL-CEBPA in combination with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumours.

Project description:Many cancer patients don’t benefit from currently-approved immune checkpoint inhibitors (ICI), suggesting that additional immunomodulation of the immunosuppressive tumour microenvironment (TME) is required. MTL-CEBPA specifically upregulates expression of master myeloid transcription factor, CEBPA, relieving myeloid-driven immunosuppression. Here, we report the safety, tolerability, pharmacokinetics, and efficacy of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumours that typically show ICI resistance. Multimodal exploratory analyses of paired patient biopsies demonstrate biological changes associated with combination treatment of MTL-CEBPA and pembrolizumab, including increased infiltration of T cell and antigen-presenting cells supporting conversion from an immune desert towards a more immune-inflamed TME. Patients with disease stabilisation demonstrate reductions in immunosuppressive myeloid cells post-treatment. Collectively, these data support a role for MTL-CEBPA in reducing immunosuppression in the TME. This study was registered at ClinicalTrials.gov (NCT04105335). This manuscript also reports proteomic data from patients treated with MTL-CEBPA in combination with sorafenib from clinical trial, OUTREACH, accessible at ClinicalTrials.gov, number NCT02716012 and reported. Stored plasma from patients from this clinical trial were analysed using OLINK as described below.

2025-05-07 | PXD060726 | Pride